I apologize in advance if my knowledge is very poor and I ask rather bad questions. But...
1. The mitochondry membrane is the only one - I read - that countains in its inner part
cardiolipin (as 20% of total lipids there), and it was found in a study (*) that 95% of CFS patients have anti-cardiolipin antibodies.
(I belong to the group with elevated IGM anticardiolipin antibodies - and the number increased with the severity of the symptoms from 1998 to now).
2. From wikipedia :
Cardiolipin serves as proton trap for oxidative phosphorylation[edit]
During the oxidative phosphorylation process catalyzed by Complex IV, large quantities of protons are transferred from one side of the membrane to another side causing a large pH change. CL is suggested to function as a proton trap within the mitochondrial membranes, thereby strictly localizing the proton pool and minimizing the changes in pH in the mitochondrial intermembrane space.
This function is due to CL’s unique structure. As stated above, CL can trap a proton within the bicyclic structure while carrying a negative charge. Thus, this bicyclic structure can serve as an electron buffer pool to release or absorb protons to maintain the pH near the membranes.[7]
Other functions[edit]
- Cholesterol translocation from outer to the inner membrane of mitochondrial
- Activates mitochondrial cholesterol side-chain cleavage
- Import protein into mitochondrial matrix
- Anticoagulant function
==> so my question is :
Could this anticardiolipin antibodies - which are present in a lot of CFS/ME patients - impair the way our mitochondries work ?
If yes, what can be done about it?
Perhaps it is another point - beside the rest and the supplementation - that has to be examined in order to make ATP ?
I have no scientific background, so please, forgive me in advance if it is a silly question,
Thanks
(*) Hokama Y, Campora CE, Hara C, Kuribayashi T, Le Huynh D, Yabusaki K. Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome. J Clin Lab Anal. 2009;23(4):210-2.